Regulatory Surveillance Over Weight Loss Drug (GLP-1) Supply Chain

In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorized sale and promotion.

With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks.

Taking cognizance of the situation, India’s Drugs Controller, in collaboration with State Regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use.

On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage.

In the recent weeks, enforcement activities were significantly scaled up. Audits and inspections were conducted at 49 entities, including: Online pharmacy warehouses, Drug wholesalers, Retailers, Wellness and slimming clinics. These inspections spanned multiple regions across the country and focused on identifying violations related to unauthorized sale, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities.

The Regulator emphasizes that patient safety remains paramount. The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners.

It is important to reiterate here that the drug has been approved in India with condition of prescription by Endocrinologists and Internal Medicine Specialist and for some indications by Cardiologists only. Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws.